Topical pharmaceutical composition of phosphodiesterase-4 inhibitor and preparation method thereof

Abstract

The invention discloses a topical pharmaceutical composition of a phosphodiesterase-4 inhibitor and a preparation method thereof, wherein the topical pharmaceutical composition comprises 0.5 to 10% bymass of apremilast active ingredient, 0.2 to 25% by mass of dimethyl sulfoxide and 65 to 99.3% by mass of a topical pharmaceutical acceptable carrier. The dosage forms of the topical pharmaceutical composition are ointments, creams, gels, coatings, lotions, tinctures, powders and liniments. The invention also discloses the preparation method of the topical pharmaceutical composition and use of the topical pharmaceutical composition. The pharmaceutical composition is not like hormonal drugs which have the side effects to cause adermotrophia after long time of use, and the pharmaceutical composition has no disadvantages such as recurrence after curing, has desired pharmacological activity and less side effects, is stable in quality and convenient to use, is safe and effective in treatment of eczema, and has strong practical application value.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a local pharmaceutical composition of phosphodiesterase-4 inhibitor and a preparation method thereof. Background technique [0002] Atopic dermatitis is one of the most common, chronic, non-infectious skin diseases, commonly known as "eczema", with the highest incidence rate among all skin diseases, and it is the number one disease in dermatology. From the perspective of pathogenesis, eczema is a kind of skin inflammatory reaction with severe itching caused by various internal and external factors, which belongs to type IV allergy, and is mainly immune injury mediated by T cells. [0003] In recent years, the incidence of eczema has been on the rise, which may be related to changes in climate and environment, the application of a large number of chemicals in life, mental stress, accelerated pace of life, and changes in dietary structure. The etiology of eczema is complicated,...

AI Technical Summary

Problems solved by technology

[0005] At present, the treatment drugs for eczema are mainly hormone creams, and antihistamines are used together to relieve itching. For generalized eczema, glucocorticoids can be taken orally or injected. For subacute and chronic eczema, suitable glucocorticoid creams, Tar-based preparations or immunomodulators, such as tacrolimus ointment and pimecrolimus ointment, are more effective in hormone therapy, but long-term use of hormone cream drugs may cause side effects of skin atrophy, and it is easy to relapse after healing, etc. Disadvantages: Add antibiotic preparations for secondary infections, and use more irritating drugs containing antibiotics, biological agents, etc., which are more harmful to the human body

In addition, there are currently researches on traditional Chinese medicine formulas for the treatment of eczema in China. The conventional external medicine is Indigo sativa powder, which is black and greasy and unhygienic. Welcome, leading to insignificant treatment effect and low cure rate

Therefore, prior art treatment of eczema has disadvantages such as relatively large side effects, high irritation, inconspicuous curative effect, and easy recurrence after healing. A kind of curative effect can replace existing therapeutic drugs with little or no side effects for the treatment of eczema. has great practical significance

Images